Abstract
This study evaluated the efficacy and toxicity of ifosfamide and doxorubicin chemotherapy regimen in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. Twenty-one patients with recurrent or metastatic NPC previously treated with platinum-based chemotherapy as adjuvant or palliative treatments who received ifosfamide 2500 mg/m(2) d 1-3, mesna 2500 mg/m(2) d 1-3, doxorubicin 60 mg/m(2) d 1, repeated every 21 d was retrospectively analyzed. Patients received a median number of three cycles of ifosfamide-doxorubicin (range: 1-6). Seven patients (33.3%) achieved partial response and no patient achieved complete response. Six (28.5%) had stable disease, whereas three (18.75%) had progressive disease. The median time to progression was 7.0 mo. Ifosfamide-doxorubicin regimen is an effective salvage regimen in patients with recurrent and metastatic NPC.
MeSH terms
-
Adolescent
-
Adult
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Alkylating / administration & dosage*
-
Cisplatin / administration & dosage
-
Cisplatin / therapeutic use
-
Combined Modality Therapy
-
Data Interpretation, Statistical
-
Disease Progression
-
Doxorubicin / administration & dosage*
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
Humans
-
Ifosfamide / administration & dosage*
-
Male
-
Middle Aged
-
Nasopharyngeal Neoplasms / drug therapy*
-
Nasopharyngeal Neoplasms / radiotherapy
-
Nasopharyngeal Neoplasms / secondary
-
Neoplasm Metastasis
-
Neoplasm Recurrence, Local
-
Retrospective Studies
-
Salvage Therapy
-
Software
-
Time Factors
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Antineoplastic Agents, Alkylating
-
Doxorubicin
-
Cisplatin
-
Fluorouracil
-
Ifosfamide